Sang Woo Yeom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sang Woo Yeom has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jong Seung Kim
Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Jeonbuk National University, Jeonju, Republic of Korea
5 shared publications - Cho Yun Jeong
Department of Medical Informatics, Jeonbuk National University, Jeonju, Korea
3 shared publications - Kyung-Hwa Nam
Department of Dermatology, Jeonbuk National University Medical School, Jeonju, Korea
3 shared publications - Min Gu Kang
Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Korea
3 shared publications - Gwangil Kim
Department of Medical Science, Graduate School, Jeonbuk National University, Jeonju, Korea
2 shared publications - Hyeok Tae Kweon
Department of Otorhinolaryngology—Head and Neck Surgery, College of Medicine, Jeonbuk National University, Jeonju, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 23 (1) , 24-37
New-onset and recurrence of psoriasis following COVID-19 vaccination: a nationwide cohort study in Korea
- 30 June 2026
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 23 (1) , 24-37
Open AccessNew-onset and recurrence of psoriasis following COVID-19 vaccination: a nationwide cohort study in Korea
- Open Access
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38
Periodontitis and Risk of Rosacea: A Nationwide Population-Based Cohort Study in Korea
Kim G, et al. Ann Dermatol. 2026 ;38:e47. https://doi.org/10.5021/ad.26.047
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38
Open AccessPeriodontitis and Risk of Rosacea: A Nationwide Population-Based Cohort Study in Korea
Kim G, et al. Ann Dermatol. 2026 ;38:e47. https://doi.org/10.5021/ad.26.047
- Open Access
- 7 October 2024
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 10 (1) , e59274
Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study
Background: Several studies have investigated the relationship between ursodeoxycholic acid (UDCA) and COVID-19 infection. However, complex and conflicting results have generated confusion in the application of these results. Objective: We aimed to investigate whether the association between UDCA and COVID-19 infection can also be demonstrated through the analysis of a large-scale cohort. Methods: This retrospective study used local and nationwide cohorts, namely, the Jeonbuk National University Hospital into the Observational Medical Outcomes Partnership common data model cohort (JBUH CDM) and the Korean National Health Insurance Service claim–based database (NHIS). We investigated UDCA intake and its relationship with COVID-19 susceptibility and severity using validated propensity score matching. Results: Regarding COVID-19 susceptibility, the adjusted hazard ratio (aHR) value of the UDCA intake was significantly lowered to 0.71 in the case of the JBUH CDM (95% CI 0.52-0.98) and was significantly lowered to 0.93 (95% CI 0.90-0.96) in the case of the NHIS. Regarding COVID-19 severity, the UDCA intake was found to be significantly lowered to 0.21 (95% CI 0.09-0.46) in the case of JBUH CDM. Furthermore, the aHR value was significantly lowered to 0.77 in the case of NHIS (95% CI 0.62-0.95). Conclusions: Using a large-scale local and nationwide cohort, we confirmed that UDCA intake was significantly associated with reductions in COVID-19 susceptibility and severity. These trends remained consistent regardless of the UDCA dosage. This suggests the potential of UDCA as a preventive and therapeutic agent for COVID-19 infection.
- 7 October 2024
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 10 (1) , e59274
Open AccessAssociation Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study
Background: Several studies have investigated the relationship between ursodeoxycholic acid (UDCA) and COVID-19 infection. However, complex and conflicting results have generated confusion in the application of these results. Objective: We aimed to investigate whether the association between UDCA and COVID-19 infection can also be demonstrated through the analysis of a large-scale cohort. Methods: This retrospective study used local and nationwide cohorts, namely, the Jeonbuk National University Hospital into the Observational Medical Outcomes Partnership common data model cohort (JBUH CDM) and the Korean National Health Insurance Service claim–based database (NHIS). We investigated UDCA intake and its relationship with COVID-19 susceptibility and severity using validated propensity score matching. Results: Regarding COVID-19 susceptibility, the adjusted hazard ratio (aHR) value of the UDCA intake was significantly lowered to 0.71 in the case of the JBUH CDM (95% CI 0.52-0.98) and was significantly lowered to 0.93 (95% CI 0.90-0.96) in the case of the NHIS. Regarding COVID-19 severity, the UDCA intake was found to be significantly lowered to 0.21 (95% CI 0.09-0.46) in the case of JBUH CDM. Furthermore, the aHR value was significantly lowered to 0.77 in the case of NHIS (95% CI 0.62-0.95). Conclusions: Using a large-scale local and nationwide cohort, we confirmed that UDCA intake was significantly associated with reductions in COVID-19 susceptibility and severity. These trends remained consistent regardless of the UDCA dosage. This suggests the potential of UDCA as a preventive and therapeutic agent for COVID-19 infection.
- Open Access
- 8 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study (Preprint)
BACKGROUND Several studies have investigated the relationship between ursodeoxycholic acid (UDCA) and COVID-19 infection. However, complex and conflicting results have generated confusion in the application of these results. OBJECTIVE We aimed to investigate whether the association between UDCA and COVID-19 infection can also be demonstrated through the analysis of a large-scale cohort. METHODS This retrospective study used local and nationwide cohorts, namely, the Jeonbuk National University Hospital into the Observational Medical Outcomes Partnership common data model cohort (JBUH CDM) and the Korean National Health Insurance Service claim–based database (NHIS). We investigated UDCA intake and its relationship with COVID-19 susceptibility and severity using validated propensity score matching. RESULTS Regarding COVID-19 susceptibility, the adjusted hazard ratio (aHR) value of the UDCA intake was significantly lowered to 0.71 in the case of the JBUH CDM (95% CI 0.52-0.98) and was significantly lowered to 0.93 (95% CI 0.90-0.96) in the case of the NHIS. Regarding COVID-19 severity, the UDCA intake was found to be significantly lowered to 0.21 (95% CI 0.09-0.46) in the case of JBUH CDM. Furthermore, the aHR value was significantly lowered to 0.77 in the case of NHIS (95% CI 0.62-0.95). CONCLUSIONS Using a large-scale local and nationwide cohort, we confirmed that UDCA intake was significantly associated with reductions in COVID-19 susceptibility and severity. These trends remained consistent regardless of the UDCA dosage. This suggests the potential of UDCA as a preventive and therapeutic agent for COVID-19 infection.
- 8 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAssociation Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study (Preprint)
BACKGROUND Several studies have investigated the relationship between ursodeoxycholic acid (UDCA) and COVID-19 infection. However, complex and conflicting results have generated confusion in the application of these results. OBJECTIVE We aimed to investigate whether the association between UDCA and COVID-19 infection can also be demonstrated through the analysis of a large-scale cohort. METHODS This retrospective study used local and nationwide cohorts, namely, the Jeonbuk National University Hospital into the Observational Medical Outcomes Partnership common data model cohort (JBUH CDM) and the Korean National Health Insurance Service claim–based database (NHIS). We investigated UDCA intake and its relationship with COVID-19 susceptibility and severity using validated propensity score matching. RESULTS Regarding COVID-19 susceptibility, the adjusted hazard ratio (aHR) value of the UDCA intake was significantly lowered to 0.71 in the case of the JBUH CDM (95% CI 0.52-0.98) and was significantly lowered to 0.93 (95% CI 0.90-0.96) in the case of the NHIS. Regarding COVID-19 severity, the UDCA intake was found to be significantly lowered to 0.21 (95% CI 0.09-0.46) in the case of JBUH CDM. Furthermore, the aHR value was significantly lowered to 0.77 in the case of NHIS (95% CI 0.62-0.95). CONCLUSIONS Using a large-scale local and nationwide cohort, we confirmed that UDCA intake was significantly associated with reductions in COVID-19 susceptibility and severity. These trends remained consistent regardless of the UDCA dosage. This suggests the potential of UDCA as a preventive and therapeutic agent for COVID-19 infection.
- 25 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (3) , E397-E399
Periodontitis and risk of alopecia areata: A nationwide population‐based cohort study in Korea
- 25 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (3) , E397-E399
Periodontitis and risk of alopecia areata: A nationwide population‐based cohort study in Korea